An international group of researchers led by Children’s Hospital of Philadelphia, Winship Cancer Institute of Emory University, and the New Approaches to Neuroblastoma Therapy Consortium showed that the targeted therapy Lorbrena (lorlatinib) is safe and effective in treating high-risk neuroblastoma.
The FDA Oncologic Drugs Advisory Committee Oct. 4 voted decisively to recommend the first-ever approval supported by a clinical trial that relied on an external control arm—using patient-level data extracted from another trial.
